Table 2.

Baseline patient characteristics

Characteristic	Lipiodol, N (%)	Lipiodol + DSM, N (%)	Total, N (%)	p-value
No. of patients	30	31	61
Sex				0.838
Male	22 (73.3)	22 (71.0)	44 (72.1)
Female	8 (26.7)	9 (29.0)	17 (27.9)
Age (years)				0.795
Mean (range)	72 (44–85)	70.5 (47–85)	71 (44–85)
Fundamental disease				0.538
Hepatitis B	6 (20)	5 (16.1)	11 (18)
Hepatitis C	11 (36.7)	11 (35.5)	22 (36.1)
Ethyltoxic	9 (30)	9 (29)	18 (29.5)
Hepatitis C + Ethyltoxic	2 (6.7)	2 (6.5)	4 (6.6)
NASH	2 (6.7)	3 (9.7)	5 (8.2)
PBC	0 (0)	1 (3.2)	1 (1.6)
Cirrhosis	25 (83.3)	26 (84.9)	51 (83.6)	0.787
Child–Pugh Class				0.281
A	24 (80)	21 (67.7)	45 (73.8)
B	6 (20)	10 (32.3)	16 (26.2)
C	0 (0)	0 (0)	0 (0)
BCLC class				0.936
A	5 (16.7)	11 (35.5)	16 (26.2)
B	22 (73.3)	11 (35.5)	33 (54.1)
C	3 (10)	9 (29)	12 (19.7)
MELD-Score				0.311
Mean (RAnge)	9 (6–17)	8 (5–20)	8 (5–20)
Localization				0.270
Right liver lobe	17 (56.7)	11 (35.5)	28 (45.9)
Left liver lobe	1 (3.3)	6 (19.4)	7 (11.5)
Both lobes	12 (40)	14 (45.1)	26 (42.6)
No. of liver lesions				0.416
1 lesion	9 (30)	15 (48.4)	24 (39.3)
2 lesions	10 (33.3)	5 (16.1)	15 (24.6)
3 lesions	5 (16.7)	4 (12.9)	9 (14.8)
4 lesions	3 (10)	4 (12.9)	7 (11.5)
≥ 5 lesions	3 (10)	3 (9.7)	6 (4.9)
Initial tumor diameter (mm)	49.54 ± 35.34	38.66 cm ± 48.30	43.15 ± 42.16	0.415
Intial tumor volume (cm3)	55.86 ± 206.03	24.56 ± 302.83	37.38 ± 259.03	0.478
No. of TACE sessions				0.491
1	2 (6.7)	2 (6.5)	4 (6.6)
2	2 (6.7)	1 (3.2)	3 (4.9)
3	26 (86.6)	28 (90.3)	54 (88.5)
AFP (ng/ml)				0.697
Mean (Range)	22.1 (1.5–5900)	18.2 (1.9–58,883)	19.2 (1.5–58,883)